

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 6108)**

### **POSITIVE PROFIT ALERT**

This announcement is made by New Ray Medicine International Holding Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that based on a preliminary review and analysis of the latest available unaudited consolidated management accounts of the Company, the consolidated net profit of the Company for the six months ended 30 June 2015 is expected to increase significantly and record an increase of not less than 40% as compared with that for the six months ended 30 June 2014. Such expected increase was mainly due to the sales of products, such as Cefamandole Nafate for Injection (注射用頭孢孟多酯鈉), Italy Levocarnitine Injection (進口左卡尼丁注射液), Clostridium Butyricum Capsule (酪酸梭菌活菌膠囊) and Cefmetazole Sodium for Injection (注射用頭孢美銻鈉) have increased significantly during the six months ended 30 June 2015, as compared to the same period in 2014, which increased the revenue and gross profit of the Group during the six months ended 30 June 2015. It is expected that the increase in the consolidated net profit of the Company will be partially offset by the increase in selling and administrative expenses and income tax expenses incurred during the six months ended 30 June 2015.

As the Company is still in the process of preparing and finalising the unaudited consolidated financial results for the six months ended 30 June 2015, information contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts of the Company and information currently available. It is not based on any data or information that has been audited or reviewed by the auditors of the Company.

Further information and other details of the Group's financial performance for the six months ended 30 June 2015 will be disclosed in the forthcoming interim results announcement to be published by the Company in due course.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**New Ray Medicine International Holding Limited**  
**LEE Chik Yuet**  
*Executive Director*

Hong Kong, 29 July 2015

*As of the date of this announcement, the executive Directors are Mr. Zhou Ling, Mr. Dai Haidong, Ms. Yang Fang and Mr. Lee Chik Yuet; and the independent non-executive Directors are Mr. Ho Hau Cheung, BBS, MH, Mr. Sung Hak Keung, Andy and Mr. Leung Chi Kin.*